Resveratrol enhances splicing of insulin receptor exon 11 in myotonic dystrophy type 1 fibroblasts

Toru Takarada; Atsushi Nishida; Atsuko Takeuchi; Tomoko Lee; Yasuhiro Takeshima; Masafumi Matsuo

doi:10.1016/j.braindev.2014.11.001

journal article Aug 01, 2015

Resveratrol enhances splicing of insulin receptor exon 11 in myotonic dystrophy type 1 fibroblasts

Toru Takarada Atsushi Nishida Atsuko Takeuchi Tomoko Lee Yasuhiro Takeshima Masafumi Matsuo

Brain and Development Vol. 37 No. 7 pp. 661-668 · Elsevier BV

View at Publisher Save 10.1016/j.braindev.2014.11.001

Topics

No keywords indexed for this article. Browse by subject →

References

36

[1]

Day "RNA pathogenesis of the myotonic dystrophies" Neuromuscul Disord (2005) 10.1016/j.nmd.2004.09.012

[2]

The myotonic dystrophies: molecular, clinical, and therapeutic challenges

Bjarne Udd, Ralf Krahe

The Lancet Neurology 2012 10.1016/s1474-4422(12)70204-1

[3]

Mahadevan "Myotonic dystrophy: is a narrow focus obscuring the rest of the field?" Curr Opin Neurol (2012) 10.1097/wco.0b013e328357b0d9

[4]

Osborne "RNA-dominant diseases" Hum Mol Genet (2006) 10.1093/hmg/ddl181

[5]

Savkur "Aberrant regulation of insulin receptor alternative splicing is associated with insulin resistance in myotonic dystrophy" Nat Genet (2001) 10.1038/ng704

[6]

Sen "Muscleblind-like 1 (Mbnl1) promotes insulin receptor exon 11 inclusion via binding to a downstream evolutionarily conserved intronic enhancer" J Biol Chem (2010) 10.1074/jbc.m109.095224

[7]

Talukdar "HnRNP A1 and hnRNP F modulate the alternative splicing of exon 11 of the insulin receptor gene" PLoS ONE (2011) 10.1371/journal.pone.0027869

[8]

Warf "Pentamidine reverses the splicing defects associated with myotonic dystrophy" Proc Natl Acad Sci USA (2009) 10.1073/pnas.0903234106

[9]

Baur "Therapeutic potential of resveratrol: the in vivo evidence" Nat Rev Drug Discov (2006) 10.1038/nrd2060

[10]

Functional characterization of the common c.-32-13T>G mutation of GAA gene: identification of potential therapeutic agents

A. Dardis, I. Zanin, S. Zampieri et al.

Nucleic Acids Research 2014 10.1093/nar/gkt987

[11]

Perez-Carro "Functional analysis and in vitro correction of splicing FAH mutations causing tyrosinemia type I" Clin Genet (2014) 10.1111/cge.12243

[12]

Hims "Therapeutic potential and mechanism of kinetin as a treatment for the human splicing disease familial dysautonomia" J Mol Med (2007) 10.1007/s00109-006-0137-2

[13]

Nishida "Chemical treatment enhances skipping of a mutated exon in the dystrophin gene" Nat Commun (2011) 10.1038/ncomms1306

[14]

Markus "Resveratrol, by modulating RNA processing factor levels, can influence the alternative splicing of pre-mRNAs" PLoS ONE (2011) 10.1371/journal.pone.0028926

[15]

Munch "Chemical hypoxia facilitates alternative splicing of EAAT2 in presymptomatic APP23 transgenic mice" Neurochem Res (2008) 10.1007/s11064-007-9540-5

[16]

Fubini "Corticosteroids alter the differentiated phenotype of articular chondrocytes" J Orthop Res (2001) 10.1016/s0736-0266(00)00060-7

[17]

Nilsen "Analysis of pre-mRNA splicing using HeLa cell nuclear extracts" Cold Spring Harbor Protoc (2013)

[18]

Baur "Are sirtuins viable targets for improving healthspan and lifespan?" Nat Rev Drug Discov (2012) 10.1038/nrd3738

[19]

Baur "Biochemical effects of SIRT1 activators" Biochim Biophys Acta (2010) 10.1016/j.bbapap.2009.10.025

[20]

Dasgupta "Resveratrol stimulates AMP kinase activity in neurons" Proc Natl Acad Sci USA (2007) 10.1073/pnas.0610068104

[21]

Frasca "Insulin receptor isoform A, a newly recognized, high-affinity insulin-like growth factor II receptor in fetal and cancer cells" Mol Cell Biol (1999) 10.1128/mcb.19.5.3278

[22]

Sciacca "Signaling differences from the A and B isoforms of the insulin receptor (IR) in 32D cells in the presence or absence of IR substrate-1" Endocrinology (2003) 10.1210/en.2002-0136

[23]

Sen "SRp20 and CUG-BP1 modulate insulin receptor exon 11 alternative splicing" Mol Cell Biol (2009) 10.1128/mcb.01709-08

[24]

Philips "Disruption of splicing regulated by a CUG-binding protein in myotonic dystrophy" Science (1998) 10.1126/science.280.5364.737

[25]

Echeverria "Muscleblind-like 1 activates insulin receptor exon 11 inclusion by enhancing U2AF65 binding and splicing of the upstream intron" Nucleic Acids Res (2014) 10.1093/nar/gkt1020

[26]

Vang "What is new for an old molecule? Systematic review and recommendations on the use of resveratrol" PLoS ONE (2011) 10.1371/journal.pone.0019881

[27]

Vang "What is new for resveratrol? Is a new set of recommendations necessary?" Ann N Y Acad Sci (2013) 10.1111/nyas.12173

[28]

Patel "Protein kinase C δ (PKCδ) splice variants modulate apoptosis pathway in 3T3L1 cells during adipogenesis: identification of PKCδII inhibitor" J Biol Chem (2013) 10.1074/jbc.m113.482638

[29]

Leiro "The anti-inflammatory activity of the polyphenol resveratrol may be partially related to inhibition of tumour necrosis factor-α (TNF-α) pre-mRNA splicing" Mol Immunol (2010) 10.1016/j.molimm.2009.10.030

[30]

Timmers "Calorie restriction-like effects of 30 days of resveratrol supplementation on energy metabolism and metabolic profile in obese humans" Cell Metab (2011) 10.1016/j.cmet.2011.10.002

[31]

Magana "Perspectives on gene therapy in myotonic dystrophy type 1" J Neurosci Res (2011) 10.1002/jnr.22551

[32]

Pushechnikov "Rational design of ligands targeting triplet repeating transcripts that cause RNA dominant disease: application to myotonic muscular dystrophy type 1 and spinocerebellar ataxia type 3" J Am Chem Soc (2009) 10.1021/ja9020149

[33]

Parkesh "Design of a bioactive small molecule that targets the myotonic dystrophy type 1 RNA via an RNA motif-ligand database and chemical similarity searching" J Am Chem Soc (2012) 10.1021/ja210088v

[34]

Gao "Antisense oligonucleotides: rising stars in eliminating RNA toxicity in myotonic dystrophy" Hum Gene Ther (2013) 10.1089/hum.2012.212

[35]

Resveratrol improves health and survival of mice on a high-calorie diet

Joseph A. Baur, Kevin J. Pearson, Nathan L. Price et al.

Nature 2006 10.1038/nature05354

[36]

Brown "Repeat dose study of the cancer chemopreventive agent resveratrol in healthy volunteers: safety, pharmacokinetics, and effect on the insulin-like growth factor axis" Cancer Res (2010) 10.1158/0008-5472.can-10-2364

Metrics

16

Citations

36

References

Details

Published: Aug 01, 2015
Vol/Issue: 37(7)
Pages: 661-668
License: View

Authors

Drug Research Department, Tokyo Research Laboratories, TOA EIYO Ltd., 2-293-3 Amanuma, Saitama 330-0834, Japan, Graduate School of Pharmaceutical Sciences, Chiba University, 1-33 Yayoicho, Inage, Chiba 263-8522, Japan, Drug Research Department, Fukushima Research Laboratories, TOA EIYO Ltd., 1 Tanaka, Yuno, Iizaka, Fukushima 960-0280, Japan, and Department of Structural Analysis, National Cardiovascular Center Research Institute, 5-7-1 Fujishirodai, Suita, Osaka 565-8565, Japan

Funding

Research on Psychiatric and Neurological Diseases and Mental Health

Nervous and Mental Disorders from the Ministry of Health, Labour and Welfare, Japan

Cite This Article

Toru Takarada, Atsushi Nishida, Atsuko Takeuchi, et al. (2015). Resveratrol enhances splicing of insulin receptor exon 11 in myotonic dystrophy type 1 fibroblasts. Brain and Development, 37(7), 661-668. https://doi.org/10.1016/j.braindev.2014.11.001

Resveratrol enhances splicing of insulin receptor exon 11 in myotonic dystrophy type 1 fibroblasts

You May Also Like